Dubai Group strikes deal with dissenting banks

New exit offer heads off arbitration. by dealReporter

Noodles & Company interviewing advisers for initial public offering

‘Secret’ S-1 filing expected as early as April. by mergermarket

Turkey’s merger control system to benefit from higher thresholds and streamlined test - lawyers

New merger notification rules will reduce the administrative burden on international deals and increase legal certainty, while easing the competition authority’s workload, Turkish lawyers tell PaRR. by PaRR

Merck’s Zetia/atorvastatin combo pill unlikely to gain FDA nod until cardiovascular impact results available

Cholesterol fighter may not reach the market till 2014. by BioPharm Insight

High hopes for buyouts in 2013 – analysis

Sponsors face limits on writing big checks as financing markets remain wide open. by dealReporter

MOFCOM favors structural remedies in horizontal mergers, division director

PaRR reveals that a senior Chinese regulator tells domestic competition conference that the reason the Chinese antitrust body often differs from US and European counterparts is that its focus is restriction of competition in China. by PaRR

Industry feels CCI demanding too much information on M&A deals

Despite light touch approach, Indian regulator continues to suffer from overly bureaucratic practices. by PaRR

Budget-cutting effort leaves anti-cartel efforts shorthanded

US government budget cuts leave cartel enforcement overwhelmed. by PaRR

DoJ has hands off Google (mostly); could risk ‘holy war’ if it attempts do-over

Department of Justice officials say they will not interfere with the Federal Trade Commission’s investigation, but joint enforcement of Google’s patents may increase tensions between the agencies. by PaRR

How Best Buy’s Schulze missed Christmas

High multiples and attractive dynamics attract PE firms to flow control sector

German competition law reform delayed until next year

Merck, BMS/AZ, Novartis face 2013 German price cuts on DPP-4 diabetes drugs

Hillshire’s doubtful growth may attract disrupter

Shire’s strong Vyvanse data and lack of abuse potential bode well for use in EU paediatrics – psychiatrists

Chinese leadership change, not island spat, at heart of MOFCOM’s Japanese bottleneck

Sprouts Farmers Markets to go public in 1H13

Permira-backed Netafim seeks China partner to grab share of irrigation market

Vertex’ Kalydeco faces UK price pushback though solid cystic fibrosis data warrants funding settlement

Sanofi/Zealand’s antidiabetic lixisenatide triggers mixed feelings on prospects for showing cardiovascular benefit

Theravance’s antibiotic Vibativ gasps for breath in hospital pneumonia

The Investment Dar debt deliberations include claim reclassification

LodgeNet plans to clear debt hurdles with lift from Colony Capital

Economist Shelanski leads candidates for FTC chairmanship

Postsecondary education M&A creeping back - Analysis

China’s inland LNG capacity expansion presents major export opportunities for foreign technology providers

Panasonic seeks to exit Sanyo-brand TV business, sources say

China to release its first biosimilars guidelines, aims to speed up drug registration process

Timing of FTC ‘Big Google’ case points toward settlement

Grandall partner to lead new antitrust-focused law firm in China

Arena’s Belviq to be unfazed by DEA scheduling as weight-loss drug not seen as addictive

Depomed’s clinical trial data for hot flashes drug Serada warrants US approval though FDA analysis gives pause

FTC chairman fights back against Phoebe Putney brief

TW Telecom seen considering sale

Smart & Final sale advances to final round

MBIA’s Bear Stearns RMBS fraud case could spark others

MetroPCS engages suitors, source says

Zabeel Investments’ debt restructuring disrupted

GSK’s Votrient expected to show noninferiority to Pfizer’s Sutent, no effect on front-line RCC uptake

Merz’s Xeomin and Belotero will impact aesthetics market post Allergan’s injunction

Proposed EMA guidelines to further steer anti-infectives developers to seek European drug approvals before US - experts

Repros in patent predicament for oral testosterone contender Androxal – lawyers

Fal Oil debt restructuring jeopardized by missing oil

Chinese companies face tough sell on US IPOs

Instagram-Facebook: Facebook sought to hide details of public hearing

Pharma continues to explore novel diabetes investments, slimmer interest in obesity

ING Japan’s corporate business being circled by Manulife

Forest Oil said to turn away suitors